Skip to main content
SpringerLink
Log in

Amino acid PET monitoring in gliomas

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Positron emission tomography (PET) with radiolabelled amino acids provides information on the behaviour of gliomas with and without blood–brain barrier (BBB) disruption. This is of importance in several clinical conditions and significantly complements findings which remain unresolved by standard MRI alone. In low-grade gliomas, amino acid PET allows early response assessment during chemotherapy which can be used to individually tailor chemotherapy duration. In high-grade gliomas, it enables the differentiation of treatment-related changes from tumor progression during cytotoxic therapy, and to identify treatment failure early during anti-angiogenic therapies. Previous studies indicate that these informations have impact on cost-effectiveness. As most of the current data are obtained from smaller retrospective studies, prospective validation is required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93.

    Article  PubMed  Google Scholar 

  2. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.

    Article  PubMed  Google Scholar 

  3. Roelcke U, Radu E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol. 1996;27(2):163–71.

    Article  CAS  PubMed  Google Scholar 

  4. Bergstrom M, Ericson K, Hagenfeldt L, Mosskin M, von Holst H, Noren G, et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr. 1987;11(2):208–13.

    Article  CAS  PubMed  Google Scholar 

  5. Haining Z, Kawai N, Miyake K, Okada M, Okubo S, Zhang X, et al. Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol. 2012;12:4. doi:10.1186/1472-6890-12-4.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30(6):868–73.

    Article  CAS  PubMed  Google Scholar 

  7. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81(4):1049–58.

    Article  CAS  PubMed  Google Scholar 

  8. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013;15(3):341–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015;56(1):9–15.

    Article  CAS  PubMed  Google Scholar 

  10. Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, et al. Dynamic (18) F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer 2015;136(9):2132–45.

    Article  CAS  PubMed  Google Scholar 

  11. Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57(3):505–11.

    Article  PubMed  Google Scholar 

  12. Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53(7):1048–57.

    Article  CAS  PubMed  Google Scholar 

  13. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22(6):633–8.

    Article  PubMed  Google Scholar 

  14. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52(6):856–64.

    Article  CAS  PubMed  Google Scholar 

  15. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 2014;82(19):1684–92.

    Article  CAS  PubMed  Google Scholar 

  16. Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61(5):484–90.

    Article  CAS  PubMed  Google Scholar 

  17. Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12(10):1078–82.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bärtschi E, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95(1):87–93.

    Article  CAS  PubMed  Google Scholar 

  19. Roelcke U, Nowosielski M, Bertero L, Crippa F, Hofer S, Bruehlmeier M, et al. Amino acid PET in non-enhancing low-grade gliomas: challenging the duration of chemotherapy. Neuro Oncol. 2012;14(Suppl 3):iii63 [abstract].

    Google Scholar 

  20. Roelcke U, von Ammon K, Hausmann O, Kaech DL, Vanloffeld W, Landolt H, et al. Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy. J Neurol Neurosurg Psychiatry 1999;66(5):644–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50(12):1962–8.

    Article  PubMed  Google Scholar 

  22. Heinzel A, Stock S, Langen KJ, Muller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging 2012;39(7):1089–96.

    Article  PubMed  Google Scholar 

  23. Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2010;37(4):685–90.

    Article  PubMed  Google Scholar 

  24. Heinzel A, Muller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, et al. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med. 2013;54(8):1217–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

U. Roelcke declares that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurology & Brain Tumor Center, Cantonal Hospital, 5001, Aarau, Switzerland

    Ulrich Roelcke MD

Authors
  1. Ulrich Roelcke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Roelcke MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roelcke, U. Amino acid PET monitoring in gliomas. memo 8, 115–118 (2015). https://doi.org/10.1007/s12254-015-0209-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0209-5

Keywords

Search

Navigation